Skip to main content

Table 1 Reported progression-free and overall survival for endometrial cancer patients treated with “sandwich” chemotherapy and radiation therapy

From: Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer

 

Overall survival

Progression-free survival

Lead Author, Year

N

UPSC/clear cell/mixed

Deaths

3-years OS

Median follow-up (months)

N

Recur, progression or death (N)

3-years PFS

Gehrig, 2004 [25]

9

100 %/0 %/0 %

0

100 %

38

N/A

1

N/A

aLupe, 2007 [26]

33

33 %/9 %/15 %

13

55 % (2-years)

21

33

14

55 % (2-years)

Secord, 2007 [27]

51

N/A

5

91 %

36

51

13

69 %

aFields, 2008 [28]

30

100 %/0 %/0 %

10

52 %

N/A

29

12

54 %

aLupe, 2009 [16]

43

35 %/7 %/14 %

14

68 %

30

41

35

53 %

Secord, 2009 [29]

45

13 %/4 %/29 %

7

88 %

36

45

11

69 %

Geller, 2010 [17]

23

52 %/4 %/0 %

3

88 %

44

23

5

80 %

aGeller, 2011 [4]

41

9 %/NA/2 %

7

90 %

28

39

11

71 %

Abaid, 2012 [5]

32

13 %/9 %/9 %

3

N/A

19

8

8

84 %

aEinstein, 2012 [6]

 

100 %/0 %0 %

 

84 % (early stage); 50 % (advanced stage)

9

20

20

N/A

Dogan, 2013 [7]

11

18 %/18 %/0 %

0

N/A

18

1

5

N/A

Lan, 2013 [30]

35

N/A

4

82 %

36

35

9

62 %

aGeller, 2011 - updated

41

9 %/NA/2 %

15

75 %

60

39

15

71 %

  1. UPSC uterine papillary serous carcinoma, PFS progression-free survival
  2. aProspective study